Abbott completes Xience PMA filing
This article was originally published in The Gray Sheet
Executive Summary
Modular PMA filing for Abbott's Xience V everolimus-eluting coronary stent is complete with submission of final clinical data package, the firm says June 1. The submission also seeks approval for the device under the Promus label, to be marketed by Boston Scientific. Abbott, which predicts FDA approval and U.S. market launch in the first half of 2008, submitted the first module of the PMA last July. The submission is supported by data from Abbott's Spirit First, Spirit II and Spirit III trials; the most recent results were presented in May at the EuroPCR meeting in Barcelona (1"The Gray Sheet" May 28, 2007, p. 3)...
You may also be interested in...
Abbott Eyes November For Xience FDA Panel Review
Abbott Laboratories has penciled in Nov. 29 to present its Xience V everolimus-eluting stent to an FDA advisory panel, the company said Sept. 24
Judge blesses Abbott Xience stent patent rights
Abbott Labs will be permitted to market future iterations of its Xience drug-eluting stent, over Israeli firm Medinol's objections, thanks to an Aug. 7 opinion handed down in the U.S. District Court, Southern District of New York, by Judge Shira Scheindlin. The decision enforces Abbott's interpretation of a February settlement agreement between the companies regarding use of Medinol's '381 patent. The settlement gives Abbott an unrestricted license to use the patent for the stent in question, as well as any related patents, despite Medinol's stance that future versions of the Abbott devices were not included. Abbott completed its Xience modular PMA filing with FDA June 1. Upon approval, it also will be marketed under the Promus label by Boston Scientific 1("The Gray Sheet" June 4, 2007, In Brief)...
EuroPCR 2007 Results Join Growing Mix Of Stent Safety Data
Drug-eluting stent makers continue to battle it out with the release of the latest safety data at the May 22-25 EuroPCR meeting in Barcelona, Spain